Viatris Inc Ord Shs Stock Price, News & Analysis

On March 1, 2021, Viatris Inc. (NASDAQ: VTRS) hosted its inaugural investor day, presenting its unique healthcare model aimed at enhancing shareholder value. CEO Michael Goettler emphasized a commitment to sustainability, financial stability, and growth through their Global Healthcare Gateway. Viatris expects 2021 to be a trough year, projecting $1 billion in synergies within three years and a dividend initiation in Q2 2021. The company plans to reduce $6.5 billion in debt by the end of 2023 and focus on improving free cash flow while building a diverse portfolio for global access to medicines.

Viatris announced its 2021 financial guidance, projecting revenues between $17.2 billion and $17.8 billion and adjusted EBITDA between $6.0 billion and $6.4 billion. The company aims for free cash flow of $2.0 billion to $2.3 billion, with a commitment to de-leveraging and enhancing cash flows. Viatris will initiate a dividend of at least 25% of free cash flow, expecting to pay approximately $400 million in dividends in 2021. A long-term leverage target of 2.5x is also set, with $6.5 billion in debt repayment anticipated by the end of 2023.

Viatris Inc. (NASDAQ: VTRS) announced a conference call for February 22, 2021, at 8 a.m. ET to discuss its 2021 financial guidance. The call can be accessed at (855) 493-3607 (US) or (346) 354-0950 (international) with ID# 3235536, as well as via their website. Additionally, Viatris will hold its first virtual Investor Day on March 1, 2021, starting at 8:30 a.m. ET, featuring key executives who will detail strategies for maximizing shareholder returns. The company emerged from the combination of Mylan and Pfizer's Upjohn business in November 2020.

Viatris Inc. (NASDAQ: VTRS) announced a favorable ruling from the U.S. District Court for the District of Kansas, granting summary judgment in favor of Mylan in its lawsuit against Sanofi regarding EpiPen products. The judgment dismisses Sanofi's allegations of anticompetitive practices and supports Mylan's defense against these claims. Over the past three years, Sanofi has unjustly sought damages and blamed Mylan for its own marketing failures with Auvi-Q, a product that Sanofi previously recalled due to dosage inaccuracies.

On December 15, 2020, Viatris Inc. (NASDAQ: VTRS) announced an unsolicited mini-tender offer from TRC Capital Corporation to acquire up to 6 million shares, representing approximately 0.497% of outstanding shares, at $16.50 each. This offer is about 4.84% lower than the recent closing price of $17.34. Viatris does not support this offer and advises stockholders against tendering their shares, citing the price's substantial discount and the minimal protections associated with mini-tender offers. Viatris emphasizes the importance of consulting financial advisors before making decisions regarding this offer.

Viatris (NASDAQ: VTRS) announced further details of its global restructuring initiative aimed at reducing costs by at least $1 billion by the end of 2024. The restructuring will impact up to 20% of its 45,000 global workforce and involve the closure or downsizing of 15 manufacturing facilities. The initiative is expected to incur pre-tax charges of $500 million to $600 million, with potential annual savings of $250 million to $300 million. The company remains committed to supply continuity and employee treatment during this transition.

Viatris (NASDAQ: VTRS) will present at the J.P. Morgan 39th Annual Healthcare Conference on January 14, 2021, at 7:30 a.m. ET, led by CEO Michael Goettler. Investors can listen live via the company's investor relations website. Additionally, Viatris will hold its inaugural Investor Day virtually on March 1, 2021, where leadership will discuss strategic plans and fiscal guidance for 2021. Webcasts for both events will be available live and archived at investor.viatris.com.

Sesame Workshop and Viatris have launched new resources aimed at supporting families' social and emotional needs during the COVID-19 pandemic. Available in multiple languages, these materials help children articulate feelings and encourage positive caregiving practices. The resources will be rolled out in various regions, including the U.S., India, and South Africa, as part of Sesame Workshop's Caring for Each Other initiative. Viatris, dedicated to public health, will share these resources with its workforce of 45,000 globally.

Viatris Inc. (NASDAQ: VTRS) received tentative FDA approval for pediatric dolutegravir tablets (10 mg) aimed at treating HIV in children, in collaboration with ViiV Healthcare and others. This approval is part of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), allowing distribution in countries with urgent needs. Pediatric dolutegravir is also recommended by the World Health Organization as a first-line treatment for eligible children. Viatris provides treatments to approximately 60% of HIV-positive children globally, emphasizing its commitment to affordable healthcare solutions.